Table 2.
Factorsa | HR | 95% CI | P value |
---|---|---|---|
Univariate analysis | |||
BMI1 | 0.58 | 0.29–1.16 | 0.124 |
POU5F1 | 0.75 | 0.38–1.47 | 0.397 |
KLF4 | 1.11 | 0.57–2.18 | 0.757 |
SMO | 0.86 | 0.43–1.68 | 0.650 |
JAG1 | 0.85 | 0.43–1.67 | 0.634 |
SPARC | 1.44 | 0.73–2.84 | 0.292 |
ST6GALNAC5 | 1.90 | 0.95–3.81 | 0.071 |
SNAI1 | 1.89 | 0.96–3.74 | 0.066 |
TNF | 1.23 | 0.63–2.41 | 0.545 |
CXCR5 | 0.77 | 0.39–1.51 | 0.448 |
GFAP | 1.00 | 0.51–1.96 | 0.995 |
DYNC1LI2 | 1.13 | 0.58–2.21 | 0.729 |
MMP3 | 1.21 | 0.62–2.37 | 0.579 |
CDH2 | 1.87 | 0.94–3.71 | 0.073 |
EGFR | 0.65 | 0.33–1.28 | 0.212 |
VCAN | 1.50 | 0.76–2.97 | 0.247 |
HGF | 0.76 | 0.39–1.50 | 0.427 |
CTNNB1 | 0.76 | 0.39–1.50 | 0.428 |
CXCR4 | 1.46 | 0.74–2.88 | 0.275 |
KIF3A | 1.47 | 0.74–2.89 | 0.269 |
GPM6A | 0.70 | 0.36–1.38 | 0.307 |
HBEGF | 0.95 | 0.48–1.86 | 0.869 |
CXCL13 | 0.99 | 0.51–1.95 | 0.985 |
TGFB2 | 0.92 | 0.47–1.80 | 0.803 |
PLP1 | 0.81 | 0.39–1.69 | 0.568 |
TWIST1 | 1.45 | 0.74–2.86 | 0.280 |
PTGS2 | 0.87 | 0.44–1.71 | 0.679 |
BPTF | 0.77 | 0.39–1.52 | 0.443 |
FABP7 | 1.92 | 0.96–3.83 | 0.066 |
GAP43 | 2.12 | 1.09–4.13 | 0.027 |
PMP2 | 2.12 | 1.05–4.30 | 0.036 |
UGT8 | 1.23 | 0.63–2.41 | 0.549 |
GPM6B | 1.00 | 0.51–1.96 | 0.990 |
FAM107A | 0.62 | 0.31–1.23 | 0.169 |
IL8 | 1.27 | 0.65–2.49 | 0.492 |
MMP9 | 1.16 | 0.59–2.27 | 0.668 |
Multivariate analysisb | |||
GAP43 | 3.29 | 1.55–7.00 | 0.002 |
SNAI1 | 1.98 | 1.00–3.95 | 0.051 |
Grade | 2.08 | 1.00–4.34 | 0.051 |
HR hazard ratio, CI confidence interval
Italic values were statistically significant (P < 0.05)
aFactors were analyzed as categorical variables, and low-expression groups or well-differentiated groups were referred
bGenes whose P values were < 0.1 in univariate analyses and clinicopathologic factors were involved in the multivariate Cox regression analysis, and the Forward LR (based on partial maximum likelihood estimation) was used to identify independent risk factors